Cloud-based software company, HumanFirst, launched a landmark platform designed to help connect pharmaceutical and biotech companies to new stores of patient-oriented measures and technologies into clinical research.
Announced on Thursday, AI-based platform allows life science organizations to access a suite of tools and resources, including the Atlas Network, an extensive evidence platform housing over 7,500 pieces of evidence, including 1,700 clinical trials from various sponsors.
In the context of healthcare and medical research, measures refer to various parameters, metrics, or data points that are collected and quantified to assess specific aspects of a patient’s health, disease progression, or treatment outcomes.
Atlas allows teams to use precise measures from its vast database of over 15,000 digital measures, along with numerous digital health technologies, questionnaires and markers derived from blood and fluids.
Additionally, Atlas Connect offers a secure workflow option for efficiently managing proprietary research data and promoting collaborative efforts across teams, thus accelerating protocol development.
Atlas Insights leverages AI to provide valuable insights, analysis and curated evidence, enabling organizations to create distinct asset and portfolio strategies.
Read more: Germany invests $2.3B to be world leader in artificial intelligence
Read more: Gen Z and millennials embrace generative AI more than other generations: survey
The HumanFirst Institute provides education services
The HumanFirst Institute provides education services, imparting best practices for harnessing the potential of precision measures and AI in clinical trials. Through this institute, teams gain essential knowledge, training and a valuable network to effectively implement precision measurement strategies and expedite the development of patient-centered treatments in the market.
“We at HumanFirst have been, and continue to be, the single largest database of AI-powered biomarkers and COAs, with our data that tracks research from more than 850 sponsors,” said Andy Corvaos, co-founder and CEO of HumanFirst.
HumanFirst’s platform offers benefits in terms of cost reduction and risk mitigation for trial portfolios. Additionally, it accelerates deployment time in clinical trials through the careful collection of evidence, helping to speed decision making regarding protocol design. By streamlining this process, organizations can save time and resources, ultimately expediting their drug development efforts.
HumanFirst’s Atlas platform offers in-depth insights into AI-powered biomarkers and clinical outcome assessments across a wide range of technologies. This includes connected sensor-generated digital health technologies, questionnaires, markers obtained from blood and bodily fluids, as well as imaging data. These insights collectively serve to expedite the drug development process.
Read more: SK Telecom invests US$100M in AI startup Anthropic for multilingual LLM development
Read more: Canadians curious about artificial intelligence, but are risks being overlooked?
Prominent medical institutions have adopted AI
AI algorithms have found valuable applications in the analysis of extensive electronic health records, primarily for disease prevention and diagnosis.
Prominent medical institutions, including The Mayo Clinic, Memorial Sloan Kettering Cancer Center and the British National Health Service, have harnessed the power of AI algorithms to develop specialized tools and solutions within their respective departments.
These algorithms play a pivotal role in improving healthcare by leveraging data-driven insights for more effective disease prevention and diagnostic processes.
Follow Joseph Morton on Twitter
joseph@mugglehead.com
